Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GP-Act III AcquisitionGPAT 16 Days Sales Outstanding is 0.00 as of Jun. 2026. GuruFocus rates GPAT with a GF Score™ of 16/100. The stock has 1 warning sign investors should review. Among 66 Diversified Financial Services companies, GP-Act III Acquisition ranks worse than 1515150% on this metric.
The historical rank and industry rank for GP-Act III Acquisition's Days Sales Outstanding or its related term are showing as below:
GPAT's Days Sales Outstanding is not ranked *
in the Diversified Financial Services industry.
Industry Median: 67.335 * Ranked among companies with meaningful Days Sales Outstanding only.
GP-Act III Acquisition's Days Sales Outstanding
stayed the same
from Jun. 2025 (0.00) to Jun. 2026 (0.00).
GP-Act III Acquisition (NAS:GPAT) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
GP-Act III Acquisition Days Sales Outstanding Related Terms
GP-Act III Acquisition Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for GP-Act III Acquisition's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GP-Act III Acquisition Days Sales Outstanding Chart
GPAT vs BWIV, PAAC, CHEC: Days Sales Outstanding Comparison
For the Shell Companies subindustry, GP-Act III Acquisition's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GP-Act III Acquisition Days Sales Outstanding vs Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, GP-Act III Acquisition's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where GP-Act III Acquisition's Days Sales Outstanding falls into.
GP-Act III Acquisition Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GP-Act III Acquisition (GPAT) has a Days Sales Outstanding of 0.00 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on GP-Act III Acquisition and its competitors. According to the industry distribution chart, GP-Act III Acquisition ranks #999999 out of 66 companies in the Diversified Financial Services industry.
Is GP-Act III Acquisition's Days Sales Outstanding too high?
GP-Act III Acquisition's current Days Sales Outstanding is 0.00. Based on the distribution chart, GP-Act III Acquisition ranks #999999 out of 66 companies in the Diversified Financial Services industry, which is in the bottom quartile relative to peers. Overall, GP-Act III Acquisition has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does GP-Act III Acquisition's Days Sales Outstanding compare to BWIV and PAAC?
According to the Diversified Financial Services industry distribution chart, GP-Act III Acquisition ranks #999999 out of 66 companies for Days Sales Outstanding. This places GP-Act III Acquisition in the lower half of its industry. The industry median Days Sales Outstanding is 67.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Diversified Financial Services company?
The median Days Sales Outstanding among Diversified Financial Services companies is 67.34, based on 66 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on GP-Act III Acquisition and its competitors. For the Diversified Financial Services industry, the median Days Sales Outstanding is 67.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GP-Act III Acquisition's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GP-Act III Acquisition stock overvalued right now?
GP-Act III Acquisition (GPAT) has a current Days Sales Outstanding of 0.00. The current Days Sales Outstanding is 0.00. GP-Act III Acquisition's overall GF Score™ is 16/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For GP-Act III Acquisition (GPAT), the current Days Sales Outstanding is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GPAT has been successfully added to your 
